EYEGUARD-B: A randomized, double-masked, placebo-controlled 12/LO/1650 study of the efficacy of gevokizumab 2 01/09/2014 OPEN N/A in the treatment of patients with Disease uveitis. Behçet’s The RELIEF Study. Polycythemia Vera Symptom Study Evaluating Ruxolitinib Versus Hydroxyurea in a CLOSED 12/WM/0348 Randomized, Multicenter, 1 15.11.2013 - In YES Double-Dummy, Phase 3 Follow-up Efficacy and Safety Study of Patient Reported Outcomes A double, randomised, multicentre study to evaluate safety and efficacy of AMG 145, compared with CLOSED ezetimibe, in hypercholesterolemic 12/WM/0290 6 23/07/2013 - In NO subjects unable to tolerate an Follow-up effective dose of a HMG-CoA reductase inhibitor 20110116 (GAUSS 2) PERUSE. A multicenter, open-label, single-arm study of pertuzumab in combination with trastuzumab and a CLOSED 12/LO/0482 taxane in first line treatment of 4 30/11/2013 - In NO patients with HER2-positive Follow-up advanced (metastatic or locally recurrent) breast cancer. FOCUS FH. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and CLOSED Efficacy of Two Different Regimens 12/NW/0014 6 22/11/2013 - In NO of Mipomersen in Patients with Follow-up Familial Hypercholesterolemia and Inadequately Controlled (MIP038) ALLOS PDX-017. A Multi-center, Randomized, Phase 3 Study of Sequential Pralatrexate Versus Observation in Patients with CLOSED Previously Undiagnosed Peripheral 10/H0718/93 7 30/08/2013 - In NO T-cell Lymphoma Who Have Follow-up Achieved an Objective Response Following Initial Treatment with CHOP-based Chemotherapy ALTERNATIVE. Comparing safety & 11/LO/1619 efficacy of AI/lapatanib/trastuzumab 5 02/01/2015 CLOSED NO in HR+HER2 MBC
12/LO/1650 EYEGUARD-B: A randomized, double-masked, placebo-controlled study of the efficacy of gevokizumab in the treatment of patients with Behçet’s Disease uveitis. 2 01/09/2014 OPEN N/A 12/WM/0348 The RELIEF Study. Polycythemia Vera Symptom Study Evaluating Ruxolitinib Versus Hydroxyurea in a Randomized, Multicenter, Double-Dummy, Phase 3 Efficacy and Safety Study of Patient Reported Outcomes 1 15.11.2013 CLOSED - In Follow-up YES 12/WM/0290 A double, randomised, multicentre study to evaluate safety and efficacy of AMG 145, compared with ezetimibe, in hypercholesterolemic subjects unable to tolerate an effective dose of a HMG-CoA reductase inhibitor 20110116 (GAUSS 2) 6 23/07/2013 CLOSED - In Follow-up NO 12/LO/0482 PERUSE. A multicenter, open-label, single-arm study of pertuzumab in combination with trastuzumab and a taxane in first line treatment of patients with HER2-positive advanced (metastatic or locally recurrent) breast cancer. 4 30/11/2013 CLOSED - In Follow-up NO 12/NW/0014 FOCUS FH. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients with Familial Hypercholesterolemia and Inadequately Controlled (MIP038) 6 22/11/2013 CLOSED - In Follow-up NO 10/H0718/93 ALLOS PDX-017. A Multi-center, Randomized, Phase 3 Study of Sequential Pralatrexate Versus Observation in Patients with Previously Undiagnosed Peripheral T-cell Lymphoma Who Have Achieved an Objective Response Following Initial Treatment with CHOP-based Chemotherapy 7 30/08/2013 CLOSED - In Follow-up NO 11/LO/1619 ALTERNATIVE. Comparing safety & efficacy of AI/lapatanib/trastuzumab in HR+HER2 MBC 5 02/01/2015 CLOSED NO